PMID- 1691405
OWN - NLM
STAT- MEDLINE
DCOM- 19900515
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 15 Suppl 2
DP  - 1990
TI  - The hemodynamics effects of ACE inhibitors in the treatment of congestive heart 
      failure.
PG  - S36-40
AB  - To determine the safety and efficacy of single oral doses of quinapril in the 
      treatment of congestive heart failure (CHF), an open-label, hemodynamic trial was 
      conducted in 11 patients with severe CHF [New York Heart Association (NYHA) class 
      III or IV] in whom previous or current therapy with diuretics and digitalis had 
      been inadequate. After participating in this single-dose trial (acute phase), all 
      11 patients were entered into a 16-week, multiple-dose investigation (chronic 
      phase). In the acute phase of the study, single oral doses of quinapril (2.5, 5, 
      and 10 mg/day) achieved beneficial hemodynamic changes within 1 h after the onset 
      of therapy. Maximal improvements in key hemodynamic variables (i.e., pulmonary 
      capillary wedge pressure, mean arterial blood pressure, cardiac output, and total 
      systemic vascular resistance) were observed within 4 h after dosing. The 
      hemodynamic changes after 16 weeks of chronic quinapril therapy (5, 10, 15, and 
      30 mg/day) were equivalent or superior to those observed after acute therapy, 
      indicating that quinapril produces a sustained hemodynamic benefit after chronic 
      oral dosing. Quinapril was shown to be safe and effective in the treatment of 
      patients with severe CHF.
FAU - Nieminen, M S
AU  - Nieminen MS
AD  - First Department of Medicine, Helsinki University Central Hospital, Finland.
FAU - Kupari, M
AU  - Kupari M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Isoquinolines)
RN  - 0 (Tetrahydroisoquinolines)
RN  - RJ84Y44811 (Quinapril)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
MH  - Exercise
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Isoquinolines/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Quinapril
MH  - *Tetrahydroisoquinolines
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1097/00005344-199000152-00007 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1990;15 Suppl 2:S36-40. doi: 
      10.1097/00005344-199000152-00007.